An analysis of the results from the Keynote-028 study revealed that the tumors with high PD-L1 expression, high expression of T-cell-inflamed genes, and high tumor mutation burden were associated with high benefit from pembrolizumab across several different tumor types [45]. Here, CD274 is linked to neoplasm.